8,180 Shares in Baxter International Inc. (NYSE:BAX) Purchased by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC purchased a new position in Baxter International Inc. (NYSE:BAX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,180 shares of the medical instruments supplier’s stock, valued at approximately $316,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BAX. Zions Bancorporation N.A. boosted its holdings in shares of Baxter International by 30.1% in the 1st quarter. Zions Bancorporation N.A. now owns 10,964 shares of the medical instruments supplier’s stock worth $850,000 after buying an additional 2,535 shares during the last quarter. Gabelli Funds LLC boosted its holdings in shares of Baxter International by 6.0% in the 1st quarter. Gabelli Funds LLC now owns 281,374 shares of the medical instruments supplier’s stock worth $21,818,000 after buying an additional 15,925 shares during the last quarter. Ancora Advisors LLC boosted its holdings in shares of Baxter International by 29.2% in the 1st quarter. Ancora Advisors LLC now owns 1,351 shares of the medical instruments supplier’s stock worth $114,000 after buying an additional 305 shares during the last quarter. Eudaimonia Partners LLC purchased a new position in shares of Baxter International in the 1st quarter worth about $340,000. Finally, KB Financial Partners LLC boosted its holdings in shares of Baxter International by 6.2% in the 1st quarter. KB Financial Partners LLC now owns 4,815 shares of the medical instruments supplier’s stock worth $373,000 after buying an additional 279 shares during the last quarter. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Trading Up 0.0 %

Shares of Baxter International stock opened at $42.71 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.04 and a debt-to-equity ratio of 1.31. The company’s 50-day moving average price is $40.89 and its 200-day moving average price is $38.00. The company has a market cap of $21.69 billion, a price-to-earnings ratio of 8.18, a PEG ratio of 2.23 and a beta of 0.62. Baxter International Inc. has a 12-month low of $31.01 and a 12-month high of $50.21.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. Baxter International had a net margin of 17.77% and a return on equity of 19.49%. The business had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.81 billion. During the same period last year, the business earned $0.88 earnings per share. The business’s quarterly revenue was up 3.5% on a year-over-year basis. On average, equities analysts expect that Baxter International Inc. will post 2.89 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 1st. Shareholders of record on Friday, March 1st will be given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 2.72%. The ex-dividend date is Thursday, February 29th. Baxter International’s payout ratio is currently 22.22%.

Analyst Ratings Changes

BAX has been the topic of several recent research reports. StockNews.com raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Friday, January 19th. UBS Group dropped their price objective on shares of Baxter International from $40.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 6th. JPMorgan Chase & Co. upped their price objective on shares of Baxter International from $38.00 to $44.00 and gave the company a “neutral” rating in a report on Friday, February 9th. Morgan Stanley dropped their price objective on shares of Baxter International from $45.00 to $39.00 and set an “equal weight” rating on the stock in a report on Monday, December 4th. Finally, Barclays upped their price objective on shares of Baxter International from $52.00 to $54.00 and gave the company an “overweight” rating in a report on Monday, February 12th. Seven investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Baxter International presently has an average rating of “Hold” and an average price target of $46.18.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.